Icon Plc (ICLR) Receives Outperform Rating from Credit Suisse Group

Credit Suisse Group restated their outperform rating on shares of Icon Plc (NASDAQ:ICLR) in a research report released on Monday morning. Credit Suisse Group currently has a $120.00 target price on the medical research company’s stock, up from their previous target price of $105.00.

Several other research analysts have also recently weighed in on ICLR. Robert W. Baird reaffirmed a buy rating and issued a $123.00 price target on shares of Icon Plc in a report on Thursday, October 12th. ValuEngine cut shares of Icon Plc from a buy rating to a hold rating in a report on Monday, October 2nd. Jefferies Group LLC upped their price target on shares of Icon Plc from $122.00 to $132.00 and gave the stock a buy rating in a report on Monday, October 9th. Zacks Investment Research cut shares of Icon Plc from a hold rating to a sell rating in a report on Wednesday, October 4th. Finally, SunTrust Banks, Inc. upgraded shares of Icon Plc from a hold rating to a buy rating and upped their target price for the stock from $93.00 to $126.00 in a research report on Monday, July 31st. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $119.33.

Shares of Icon Plc (ICLR) opened at 115.68 on Monday. The firm has a market cap of $6.25 billion, a P/E ratio of 23.46 and a beta of 0.59. The firm has a 50 day moving average price of $113.18 and a 200-day moving average price of $98.33. Icon Plc has a one year low of $73.76 and a one year high of $117.53.

Icon Plc (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.01. The firm had revenue of $431.00 million for the quarter, compared to analysts’ expectations of $430.68 million. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. Analysts forecast that Icon Plc will post $5.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Icon Plc (ICLR) Receives Outperform Rating from Credit Suisse Group” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/17/icon-plc-iclr-receives-outperform-rating-from-credit-suisse-group.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. IHT Wealth Management LLC boosted its position in Icon Plc by 16.9% during the second quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after buying an additional 24 shares during the period. IFP Advisors Inc boosted its position in Icon Plc by 3.0% during the second quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock valued at $225,000 after buying an additional 67 shares during the period. Huntington National Bank boosted its position in Icon Plc by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after buying an additional 77 shares during the period. Bangor Savings Bank boosted its position in Icon Plc by 1.4% during the second quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock valued at $1,128,000 after buying an additional 161 shares during the period. Finally, Raymond James Financial Services Advisors Inc. booste

Several other research analysts have also recently weighed in on ICLR. Robert W. Baird reaffirmed a buy rating and issued a $123.00 price target on shares of Icon Plc in a report on Thursday, October 12th. ValuEngine cut shares of Icon Plc from a buy rating to a hold rating in a report on Monday, October 2nd. Jefferies Group LLC upped their price target on shares of Icon Plc from $122.00 to $132.00 and gave the stock a buy rating in a report on Monday, October 9th. Zacks Investment Research cut shares of Icon Plc from a hold rating to a sell rating in a report on Wednesday, October 4th. Finally, SunTrust Banks, Inc. upgraded shares of Icon Plc from a hold rating to a buy rating and upped their target price for the stock from $93.00 to $126.00 in a research report on Monday, July 31st. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $119.33.

Shares of Icon Plc (ICLR) opened at 115.68 on Monday. The firm has a market cap of $6.25 billion, a P/E ratio of 23.46 and a beta of 0.59. The firm has a 50 day moving average price of $113.18 and a 200-day moving average price of $98.33. Icon Plc has a one year low of $73.76 and a one year high of $117.53.

Icon Plc (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.01. The firm had revenue of $431.00 million for the quarter, compared to analysts’ expectations of $430.68 million. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. Analysts forecast that Icon Plc will post $5.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Icon Plc (ICLR) Receives Outperform Rating from Credit Suisse Group” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/17/icon-plc-iclr-receives-outperform-rating-from-credit-suisse-group.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. IHT Wealth Management LLC boosted its position in Icon Plc by 16.9% during the second quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after buying an additional 24 shares during the period. IFP Advisors Inc boosted its position in Icon Plc by 3.0% during the second quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock valued at $225,000 after buying an additional 67 shares during the period. Huntington National Bank boosted its position in Icon Plc by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after buying an additional 77 shares during the period. Bangor Savings Bank boosted its position in Icon Plc by 1.4% during the second quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock valued at $1,128,000 after buying an additional 161 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its position in Icon Plc by 5.0% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 3,537 shares of the medical research company’s stock valued at $282,000 after buying an additional 168 shares during the period. Institutional investors and hedge funds own 91.54% of the company’s stock.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply